A Clinicobiological Database in Metastatic Digestive Cancers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-09-12

Study Completion Date

2031-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Creation of a collection of blood samples that will be collected before and then under treatment in patients with digestive adenocarcinoma during the 1st and 2nd metastatic line and which, depending on scientific progress, can be used for research projects aimed at developing tailored patient management strategies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Molecular Characterisation of Colorectal Cancer Peritoneal Metastases

NCT05513716

Colorectal Cancer Metastatic

RECRUITING

Study of Genetic and Cellular Immunological Parameters Predictive of Disease-free Survival in Patients With Metastatic Cancer

NCT02838381

Metastatic Cancer

COMPLETED NA

Medical and Surgical Management of Patients With Brain Metastases

NCT03981016

Central Nervous System Tumor

COMPLETED NA

The Enzymatic Activity of Lymphocyte Dihydropyrimidine Dehydrogenase DPD in the Blood as a Predictive and Prognostic Factor in Patients With Digestive Cancer in the First or Second Metastatic Line

NCT03205735

Metastatic or Locally-advanced Digestive Cancer

UNKNOWN

Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors

NCT03149523

Colorectal Adenocarcinoma Hepatic Carcinoma Kidney Adenocarcinoma

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Digestive cancers account for 30% of all cancers. The most common of these colorectal cancer (CRC) is the third most common cause of cancer in the world.

In the metastatic phase, patients with digestive cancers generally benefit from medical treatment based on cytotoxic chemotherapy, which can be combined with targeted therapy in certain locations. Their use is based on demonstrating a significant improvement in the overall survival of patients.

However, the therapeutic choice and follow-up of these treatments as a the first line treatment and beyond remain difficult given a cruel lack of biomarkers capable of predicting the response to these different molecules upstream but also usable during treatment to evaluate their efficacy or identify the development of secondary resistance mechanisms.

Indeed, the only biomarkers currently validated and used before the initiation of anti-cancer treatment to stratify patients are:

* the search for mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) and neuroblastoma rat sarcoma viral oncogene (NRAS) oncogenes as predictive factors for non-response to anti-Epidermal Growth Factor receptor (EGFR) in colorectal adenocarcinomas.
* the search for overexpression of the human epidermal growth factor (HER2) receptor to introduce trastuzumab treatment in esophageal adenocarcinomas.

In addition, they are conventionally determined from tumor tissue, which requires an invasive biopsy or surgical sampling that is difficult to repeat over time.

In this context, it seems essential to us to identify new parameters allowing a better personalization of anti-cancer treatments, by favouring blood biomarkers that have the advantage of being evaluated in a minimally invasive manner and therefore be repeated to be able to judge tumor dynamics.

To this end, we propose the creation of a collection of samples that will be collected before and then under treatment in patients with digestive adenocarcinoma in the 1st and 2nd metastatic line and which, depending on scientific progress, can be used for research projects aimed at developing tailored patient management strategies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Digestive System Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Biological collection

For all the patients include in the study :

\- Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment

In parallel to this biological collection, standardized clinical data will be entered into a database

Group Type EXPERIMENTAL

Biological collection

Intervention Type OTHER

\- Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biological collection

\- Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female ≥ 18 years old
2. Histological documentation of adenocarcinoma of the colon or rectum, small intestine, pancreas, stomach, bile duct, oesophagus
3. Patient who will receive a first or second line metastatic chemotherapy and/or targeted therapy
4. Informed consent form (ICF) signed

Exclusion Criteria

1. Male or female \< 18 years old
2. Non-adenocarcinoma histological type
3. Patient already undergoing specific treatment (chemotherapy and/or targeted therapy) in 1st or 2nd metastatic line
4. Pregnant and/or breastfeeding woman
5. Patient not affiliated to a social security system
6. Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons
7. Patient who is included in a Phase I-II therapeutic trial modifying usual management and involving additional and specific blood samples

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No